Global Clinical Laboratory Tests Market By Type (Complete Blood Count, HGB/HCT, and Others), By End Use (Central Laboratories, Primary Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Clinical Laboratory Tests Market Overview:

The clinical laboratory test market size is expected to be worth around USD 452.41 Billion by 2032 from USD 204.19 Billion in 2021, growing at a CAGR of 7.5% during the forecast period from 2022 to 2032.

The market’s growth is due to the increasing prevalence of chronic disease and the growing awareness of health-conscious consumers. Investments in diagnosing target diseases, such as diabetes and cardiovascular disorders, are driving increasing demand for laboratory tests. Diagnosing diabetes mellitus is possible with clinical laboratory tests.

According to an International Diabetes Federation article, around 463 million Americans had diabetes in 2019 and that number may reach 700 million soon.

Increasing investments in the development of advanced laboratory testing procedures, technological advances in clinical diagnostic techniques and equipment, and an increase in patient-centered approaches to disease management, mainly chronic and viral diseases, are expected to drive the growth of the clinical laboratory test market.

Global Clinical Laboratory Tests Market Scope:

Type analysis

Market segments for the clinical laboratory test market are complete comprehensive metabolic panel testing, Complete Blood Count (CBC), BUN creatinine, Basic Metabolic Panel, and HGB/HCT tests. Electrolytes testing, lipid panel testing, liver panel testing, and renal panel testing.

The increasing prevalence of lifestyle-induced illnesses such as obesity and metabolic abnormalities made basic metabolic tests an important part of the global marketplace for clinical laboratory testing in 2021. Growing awareness about the prevalence of diabetes, cardiovascular disorders, and lipid panel tests is expected to make this the fastest-growing segment in the next few years.

According to data from the World Health Organization (WHO), more than 17 million people per year die from cardiovascular problems due to poor lifestyles, increased blood pressure, and high blood cholesterol.

The liver panel segment has been further split into liver cirrhosis, bone disease, liver cancer, and bile tube obstruction. and autoimmune conditions. Hepatitis had the largest share of the market growth in 2021, while the liver cancer segment was predicted to be the fastest-growing over the forecast time, due to increased lifestyle disorders and higher alcohol intake.

End-Use analysis

Based on end-use the market for clinical laboratory tests can be divided into primary clinic-based laboratories, hospital-based laboratories, stand-alone laboratories, central laboratories, and specialist labs. In 2021, the market was dominated mainly by a central laboratory. The central laboratory segment would grow if there were more central laboratories, including Q2 Solutions, Phoenix Lab, CIRION BioPharma Research Inc., LLC, Covance Inc., Pharmaceutical Product Development, and Eurofins Scientific.

A significant growth rate is expected for the primary clinic sector over the forecast period due to the growing demand to quickly obtain test results. The forecast period will see the segment grow because of increased awareness by patients and physicians about the benefits of laboratory tests in clinics. The segment growth is expected to be driven by key technological advances like portable and quick analyzers.

Кеу Маrkеt Ѕеgmеntѕ

By Type

• BUN Creatinine Tests
• HGB/HCT
• Complete Blood Count
• Basic Metabolic Panel
• Liver Panel
  • Hepatitis
  • Liver Cirrhosis
  • Bile Duct Obstruction
  • Others
• Lipid Panel
• Renal Panel

By End-Use

• Central Laboratories
  • Complete Blood Count
  • Basic Metabolic Panel
  • HGB/HCT
  • BUN Creatinine Tests
• Primary Clinics
  • Electrolytes Testing
  • Comprehensive Metabolic Panel
  • Liver Panel
  • HbA1c Tests

Market Dynamics:

Market research in clinical laboratory testing provides a critical evaluation of current lucrative avenues and major drivers. It also examines investment and research trends of well-established players in emerging markets to help them tap into their growth potential.

High-quality, high-quality diagnostic testing is a critical pillar for quality patient care. This drive has been the driving force behind the rapid growth of the clinical laboratory testing market. This market has seen an increase in chronic diseases and the morbidity of other non-communicable disorders.

Many chronic diseases are likely to rise as a result of increased obesity, insufficient exercise, and unhealthy diets. Clinical laboratory tests will be more in demand as patients and healthcare professionals become more aware of the necessity for regular body profiling.

Regional Analysis

North America dominated 2021 the global marketplace for clinical laboratory tests with a 51.9% market share. The regional market’s dominance is supported by the rising use of advanced diagnostic tools and growing test volumes.

Clinical laboratory tests are expected to be in demand due to rising cancer rates, the increasing geriatric population, and the increased penetration of advanced diagnostic tools.

The Asia Pacific will be the fastest-growing market in the future due to improved healthcare infrastructure and the adoption of advanced diagnostic techniques in emerging markets like India, China, and India. The Asia Pacific market is a major driver for clinical laboratory testing.

Key Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Competitive Landscape:

Companies are increasingly focusing their efforts on strategic partnerships, mergers, and acquisitions in order to expand their presence in the market of clinical laboratory tests. Charles River 2018 acquired MPI research, a premier non-clinical contract research agency that provides comprehensive testing to various biopharmaceutical/medical device companies.

Charles River’s ability to meet its long-term goals will be enhanced by the acquisition of MPI research in 2018. This organization provides comprehensive testing services to different biopharmaceutical and medical device companies.

The major key companies in the clinical laboratory test market are OPKO Health, Inc., Charles River, NeoGenomics Laboratories, Inc., Fresenius Medical Care, Sonic Healthcare Ltd., SYNLAB International GmbH, Sonic Healthcare Limited, Siemens Healthcare Private Limited, Cerba HealthCare, Science Inc., Bioscientia Institut für Medizinische Diagnostik GmbH and Others.

Маrkеt Кеу Рlауеrѕ:

• Abbott
• ARUP Laboratories
• OPKO Health, Inc.
• Charles River
• Sonic Healthcare Limited
• NeoGenomics Laboratories, Inc.
• Genoptix, Inc.
• Health scope Ltd
• Siemens Healthcare Private Limited
• Tulip Diagnostics (P) Ltd.
• Sonic Healthcare
• Other Key Players

For the Clinical Laboratory Test Market research study, the following years have been considered to estimate the market size: